russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2017-5-132-139russjcardiol-2321Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON THE ISSUEКОМБИНИРОВАННАЯ АНТИГИПЕРТЕНЗИВНАЯ ТЕРАПИЯ: “НЕДОСТАТОЧНО ИЗУЧЕННЫЕ” КОМБИНАЦИИCOMBINATION ANTIHYPERTENSION THERAPY: THE “UNDERRESEARCHED” COMBINATIONSКотовскаяЮ. В.KotovskayaYu. V.

Доктор медицинских наук, профессор, зав. кафедрой кардиологии и персонифицированной медицины факультета повышения квалификации медицинских работников, зав. лабораторией сердечно-сосудистого старения

kotovskaya@bk.ruРунихинаН. К.RunikhinaN. К.

Доктор медицинских наук, заместитель директора

ОстапенкоВ. С.OstapenkoV. S.

Ассистент кафедры болезней старения факультета дополнительного образования, врач-гериатр

ФГАОУ ВО Российский университет дружбы народов; ФГБОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России, ОСП Российский геронтологический научно-клинический центрРоссияPeoples’ Friendship University of Russia; N. I. Pirogov Russian National Research Medical University (RNRMU), Russian Gerontology Scientific-Clinical CenterRussian FederationФГБОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России, ОСП Российский геронтологический научно-клинический центрРоссияN. I. Pirogov Russian National Research Medical University (RNRMU), Russian Gerontology Scientific-Clinical CenterRussian Federation20170906201705132139Copyright © Котовская Ю.В., Рунихина Н.К., Остапенко В.С., 20172017Котовская Ю.В., Рунихина Н.К., Остапенко В.С.Kotovskaya Y.V., Runikhina N.К., Ostapenko V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2321

Снижение повышенного артериального давления (АД) и поддержание его целевого уровня является главным путем снижения сердечно-сосудистой заболеваемости и смертности у пациентов с артериальной гипертонией. Для эффективного снижения АД большинству пациентов требуется комбинированная антигипертензивная терапия. В статье обсуждаются вопросы преимуществ и нежелательных явлений отдельных комбинаций антигипертензивных препаратов. Подробно рассматривается вопрос комбинации бета-адреноблокатора и блокатора ренин-ангиотензин-альдостероновой системы, которая, по данным российских наблюдательных

Decrease of blood pressure (BP) and its maintenance on target level is the main factor for cardiovascular mortality and morbidity reduction in hypertensive patients. For effective BP decrease most patients need combination therapy. The article is focused on benefits and adverse events of some combinations. In details an issue considered, on the combination of beta-blocker and renin-angiotensine-aldosteron system blocker, which, by the data from Russian observational programs, is the leader among two-component combinations. R

артериальная гипертониякомбинированная терапиянежелательные явления.программзанимает лидирующее место среди свободных двухкомпонентных комбинацийarterial hypertensioncombination therapyadverse eventsReferencesMancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.Chazova IE, Oshepkova EV, Zhernakova YuV. Clinical guidelines diagnostics and treatment of arterial hypertension. Kardiologicheskij Vestnik 2015; 1: 3-31. Russian (Чазова И. Е., Ощепкова Е.В., Жернакова Ю.В. Клинические рекомендации по диагностике и лечению артериальной гипертонии. Кардиологический Вестник 2015; 1: 3-31).Chazova IE, Oshepkova EV, Zhernakova YuV. Clinical guidelines diagnostics and treatment of arterial hypertension. Kardiologicheskij Vestnik 2015; 1: 3-31. Russian (Чазова И. Е., Ощепкова Е.В., Жернакова Ю.В. Клинические рекомендации по диагностике и лечению артериальной гипертонии. Кардиологический Вестник 2015; 1: 3-31).ALLHAT officers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.ALLHAT officers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.Pepine CJ, Handberg EM, Cooper-De Hoff RM, et al. INVEST investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805-16.Pepine CJ, Handberg EM, Cooper-De Hoff RM, et al. INVEST investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805-16.Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Dalhof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Dalhof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Wald DS, Law M, Morris JK, et al. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am JMed 2009; 122: 290-300.Wald DS, Law M, Morris JK, et al. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am JMed 2009; 122: 290-300.Kobalava ZD, Kotovskaya YV, Moiseeva VS. Arterial hypertension: the keys to diagnosis and treatment. A guide for doctors. Moscow. Izdatel’stvo “GEOTAR Media” 2009 p.864. Russian (Кобалава Ж.Д., Котовская Ю.В., Моисеев В.С.. Артериальная гипертония: ключи к диагностике и лечению. Руководство для врачей. М: Изд-во “ГЭОТАР Медиа”. 2009. 864 с.).Kobalava ZD, Kotovskaya YV, Moiseeva VS. Arterial hypertension: the keys to diagnosis and treatment. A guide for doctors. Moscow. Izdatel’stvo “GEOTAR Media” 2009 p.864. Russian (Кобалава Ж.Д., Котовская Ю.В., Моисеев В.С.. Артериальная гипертония: ключи к диагностике и лечению. Руководство для врачей. М: Изд-во “ГЭОТАР Медиа”. 2009. 864 с.).ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288: 2981-97.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288: 2981-97.Morris DR, Cunningham MA, Ahimastos AA, et al. TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial. Trials 2015; 16: 274.Morris DR, Cunningham MA, Ahimastos AA, et al. TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial. Trials 2015; 16: 274.Kobalava ZD, Kotovskaya YV, Lukyanova EA. Combined therapy of arterial hypertension with a fixed combination of perindopril A / amlodipine in real clinical practice: organization and main results of the CONSTANTA program. Kardiologiia 2013; 53(6): 25-34. Russian (Кобалава Ж. Д., Котовская Ю. В., Лукьянова Е. А. от имени врачей-участников программы КОНСТАНТА. Комбинированная терапия артериальной гипертонии фиксированной комбинацией периндоприл А/амлодипин в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология 2013; 53(6): 25-34).Kobalava ZD, Kotovskaya YV, Lukyanova EA. Combined therapy of arterial hypertension with a fixed combination of perindopril A / amlodipine in real clinical practice: organization and main results of the CONSTANTA program. Kardiologiia 2013; 53(6): 25-34. Russian (Кобалава Ж. Д., Котовская Ю. В., Лукьянова Е. А. от имени врачей-участников программы КОНСТАНТА. Комбинированная терапия артериальной гипертонии фиксированной комбинацией периндоприл А/амлодипин в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология 2013; 53(6): 25-34).Leonova MV, Shteinberg LL, Alimova EE, et al. Results of pharmacoepidemiological study of arterial hypertension PIFAGOR IV (interview with patients with arterial hypertension) Systemic Hypertension 2015; 12(3): 11-8. Russian (Леонова МВ, Белоусов ЮБ, Штейнберг ЛЛ, Алимова ЭЭ, Смирнова ЕП, Белоусов ДЮ и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Системные гипертензии. 2015; 12 (3): 11-8.Leonova MV, Shteinberg LL, Alimova EE, et al. Results of pharmacoepidemiological study of arterial hypertension PIFAGOR IV (interview with patients with arterial hypertension) Systemic Hypertension 2015; 12(3): 11-8. Russian (Леонова МВ, Белоусов ЮБ, Штейнберг ЛЛ, Алимова ЭЭ, Смирнова ЕП, Белоусов ДЮ и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Системные гипертензии. 2015; 12 (3): 11-8.Cody RJ. The integrated effects of angiotensin II .Am. J. Cardiol. 1997, 79: 9-11.Cody RJ. The integrated effects of angiotensin II .Am. J. Cardiol. 1997, 79: 9-11.Cox SL, Story DF, Ziogas J. Multiple prejunctional actions of angiotensin II on noradrenergic transmission in the caudal artery of the rat. Br. J. Pharmacol. 1996; 119: 976-84.Cox SL, Story DF, Ziogas J. Multiple prejunctional actions of angiotensin II on noradrenergic transmission in the caudal artery of the rat. Br. J. Pharmacol. 1996; 119: 976-84.Weber MA, Basile J, Stapff M, et al. Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens (Greenwich) 2012; 14(9): 588-92.Weber MA, Basile J, Stapff M, et al. Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens (Greenwich) 2012; 14(9): 588-92.Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three betablockers. J. Clin. Pharmacol. 2003; 28(3): 179-86.Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three betablockers. J. Clin. Pharmacol. 2003; 28(3): 179-86.Leopold G, Pabst J, Ungethum W, Buhring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1 selective adrenoreceptor antagonist. J. Clin. Pharmacol. 1986; 26: 616-21.Leopold G, Pabst J, Ungethum W, Buhring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1 selective adrenoreceptor antagonist. J. Clin. Pharmacol. 1986; 26: 616-21.Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system. J. Hypertens. 2004; 22 (12): 2253-61.Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system. J. Hypertens. 2004; 22 (12): 2253-61.Kintscher U. ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. J. Hypertens. Suppl. 2009; 27(2): 36-9.Kintscher U. ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. J. Hypertens. Suppl. 2009; 27(2): 36-9.Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 2005; 4:6. DOI: 10.1186/1475-2840-4-6Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 2005; 4:6. DOI: 10.1186/1475-2840-4-6Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials. Int. J. Cardiol. 2012; 156 (1): 92-6.Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials. Int. J. Cardiol. 2012; 156 (1): 92-6.Aleman G, Torres N, Tovar AR. Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development. Rev. Invest. Clin. 2004; 56 (3): 351-67.Aleman G, Torres N, Tovar AR. Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development. Rev. Invest. Clin. 2004; 56 (3): 351-67.Derosa G, Ragonesi P, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, gluсose metabolism and lipid profile in hypertensive, type II diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 2004; 27 (7): 457-64.Derosa G, Ragonesi P, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, gluсose metabolism and lipid profile in hypertensive, type II diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 2004; 27 (7): 457-64.Mallion JM, Siche JP, Lacourciere Y, the telmisartan blood pressure monitoring group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J. Hum. Hypertens. 1999; 13 (10): 657-64.Mallion JM, Siche JP, Lacourciere Y, the telmisartan blood pressure monitoring group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J. Hum. Hypertens. 1999; 13 (10): 657-64.Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: metaanalysis of titration to response studies. Blood Press. Monit. 2003; 8 (3): 111-7.Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: metaanalysis of titration to response studies. Blood Press. Monit. 2003; 8 (3): 111-7.Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens. Res. 2008; 31 (5): 921-9.Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens. Res. 2008; 31 (5): 921-9.Lacourciere Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am. J. Hypertens. 2006;19: 104-12.Lacourciere Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am. J. Hypertens. 2006;19: 104-12.Nalbantgil I, Nalbantgil S, Ozerkan F, et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension . Int. J. Clin. Pract. 2004; 58 (145): 50-4.Nalbantgil I, Nalbantgil S, Ozerkan F, et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension . Int. J. Clin. Pract. 2004; 58 (145): 50-4.Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am. J. Ther. 1999; 6 (3): 161-6.Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am. J. Ther. 1999; 6 (3): 161-6.Haasis R, Bethge H. Exercise blood pressure and heart rate redaction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double blind study (BISOMED). Eur Heart J 1987; 8: 103-13.Haasis R, Bethge H. Exercise blood pressure and heart rate redaction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double blind study (BISOMED). Eur Heart J 1987; 8: 103-13.Yang T, Jiang Y, Hao Y, et al. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res. 2017; 40(1): 79-86.Yang T, Jiang Y, Hao Y, et al. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res. 2017; 40(1): 79-86.Gosse P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (5): 145-50.Gosse P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (5): 145-50.Buhler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol. 1986; 8 (11): 22-7.Buhler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol. 1986; 8 (11): 22-7.Kukes VG, Ostroumova OD, Mamaev VI, et al. Efficacy and safety of various betablockers in patients with isolated systolic hypertension and concomitant diabetes mellitus and obstructive pulmonary disease. Ter. arch. 2003; 75(8): 43-7. Russian (Кукес В. Г., Остроумова О. Д., Мамаев В. И. и др. Эффективность и безопасность различных бета-блокаторов у пациентов с изолированной систолической гипертонией и сопутствующими сахарным диабетом и обструктивными болезнями легких. Тер арх 2003; 75(8): 43-7).Kukes VG, Ostroumova OD, Mamaev VI, et al. Efficacy and safety of various betablockers in patients with isolated systolic hypertension and concomitant diabetes mellitus and obstructive pulmonary disease. Ter. arch. 2003; 75(8): 43-7. Russian (Кукес В. Г., Остроумова О. Д., Мамаев В. И. и др. Эффективность и безопасность различных бета-блокаторов у пациентов с изолированной систолической гипертонией и сопутствующими сахарным диабетом и обструктивными болезнями легких. Тер арх 2003; 75(8): 43-7).Pucci G, Ranalli MG, Battista F, Schillaci G. Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure: Systematic Review and Meta-Analysis of Randomized Trials in Hypertension. Hypertension. 2016; 67(2): 316-24.Pucci G, Ranalli MG, Battista F, Schillaci G. Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure: Systematic Review and Meta-Analysis of Randomized Trials in Hypertension. Hypertension. 2016; 67(2): 316-24.Zhou WJ, Wang RY, Li Y, et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One 2013; 10; 8(9).Zhou WJ, Wang RY, Li Y, et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One 2013; 10; 8(9).Eguchi K, Hoshide S, Kario K. Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness and Baroreflex Sensitivity. Am J Hypertens. 2015; 28(7): 858-67.Eguchi K, Hoshide S, Kario K. Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness and Baroreflex Sensitivity. Am J Hypertens. 2015; 28(7): 858-67.Kobalava ZD, Kotovskaya YV, Bogomaz AV. The fixed combination of bisoprolol and amlodipine neutralizes the effect of β-adrenoblocker on the indices of the central pulse wave in patients with arterial hypertension. Kardiologiia 2015; 12: 11-6. Russian (Кобалава ЖД, Котовская ЮВ, Богомаз АВ. Фиксированная комбинация бисопролола и амлодипина нивелирует влияние β-адреноблокатора на показатели центральной пульсовой волны у больных артериальной гипертонией. Кардиология 2015; 12: 11-6).Kobalava ZD, Kotovskaya YV, Bogomaz AV. The fixed combination of bisoprolol and amlodipine neutralizes the effect of β-adrenoblocker on the indices of the central pulse wave in patients with arterial hypertension. Kardiologiia 2015; 12: 11-6. Russian (Кобалава ЖД, Котовская ЮВ, Богомаз АВ. Фиксированная комбинация бисопролола и амлодипина нивелирует влияние β-адреноблокатора на показатели центральной пульсовой волны у больных артериальной гипертонией. Кардиология 2015; 12: 11-6).

The authors declare that there are no conflicts of interest present.